What changed for Narcolepsy
A plain English summary of what recently moved in the public data Voxsanity tracks for Narcolepsy. Updated from government registries. Not medical advice.
How to read these changes: every figure on this page is the difference between two snapshots of what Voxsanity had tracked on each date. Voxsanity only began taking daily snapshots in July 2026 and is still ingesting the public registries, so a rise here is mostly our own coverage expanding rather than new research appearing. Read it as our tracked coverage growing, not as a claim about real-world research changing this fast: it overstates how much actually changed.
Comparing the two most recent snapshots, 27 July 2026 and 28 July 2026.
- Trials on record 154 to 149 (-5)
Newly subsidised on the PBS
No medicines were newly subsidised on the PBS for Narcolepsy in July 2026. Voxsanity tracks 4 PBS-subsidised medicines for this condition; none of them was listed for the first time this month.
Source: Pharmaceutical Benefits Scheme (PBS), © Commonwealth of Australia. Data used and redistributed under permission; not modified from its original wording where displayed verbatim.
Past updates
Tracking began in July 2026. Month on month changes will appear here once a second month of data has been recorded. Until then, the comparison above shows the most recent movement.
Recent trend
Weekly, most recent weeks (fills out to a monthly trend as history grows).
Recent trial results
Trials tracked for Narcolepsy that have reported results to a public registry.
AI generated results summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
-
NCT06505031 · results posted 16 July 2026
According to the results reported on ClinicalTrials.gov, this trial (NCT06505031) enrolled 105 participants — 35 received a placebo and 70 received the investigational medicine oveporexton — to study its effects on narcolepsy symptoms over 12 weeks. The trial measured two main things: how long participants could stay awake during a formal wakefulness test (called the Maintenance of Wakefulness Test, or MWT), and how sleepy they felt day-to-day using a standard questionnaire called the Epworth Sleepiness Scale (ESS, scored 0–24, where higher means sleepier). A number of additional measures were...
Read the full trial page · View reported results on ClinicalTrials.gov ↗
-
NCT05709873 · results posted 30 June 2026
According to the results reported on ClinicalTrials.gov, this trial involved just seven people in total — four in a group receiving a therapy called Imagery Rehearsal Therapy (IRT), and three in a group receiving IRT combined with an additional technique called Targeted Dream Control (IRT+TDC). Six of the seven participants completed the study. The trial was measuring how often participants experienced nightmares, how severe those nightmares were, and also looked at anxiety symptoms, depression symptoms, how often participants acted out their dreams, and how often they talked in their sleep —...
-
NCT05869773 · results posted 24 April 2026
According to the results reported on ClinicalTrials.gov, this trial looked at a treatment called JZP258 and measured its effect on blood pressure — specifically systolic blood pressure (the "top number" in a blood pressure reading, measured in millimetres of mercury, or mmHg). A total of 155 people entered an initial screening phase, of whom 67 went on to take part in the treatment period. Of those 67, 60 people completed the treatment period, while 7 did not finish. The reported data shows changes in systolic blood pressure from the start of the treatment period to the end. For the main (pri...
View reported results on ClinicalTrials.gov ↗ · Linked publication on PubMed ↗
-
NCT06179407 · results posted 14 April 2026
According to the results reported on ClinicalTrials.gov, this trial involved two groups (called Panel A and Panel B), though all participants with reported data were in Panel A. Nine people started the trial. Over roughly seven weeks, participants received single doses of an investigational drug called MK-6552 at four different dose levels (0.1 mg, 0.25 mg, 0.5 mg, and 1 mg), as well as repeated daily doses over seven-day periods, and a placebo (a dummy treatment with no active ingredient). The trial was primarily measuring how MK-6552 moves through the body — how quickly it is absorbed, how h...
-
NCT04072380 · results posted 13 January 2025
According to the results reported on ClinicalTrials.gov, this trial (NCT04072380) tested two doses of an investigational medicine called SUVN-G3031 (2 mg and 4 mg) against a placebo (an inactive dummy treatment) in people with excessive daytime sleepiness. A total of 190 people were enrolled across the three groups — 63 in the 2 mg group, 64 in the 4 mg group, and 63 in the placebo group. The trial's main measurement was the Epworth Sleepiness Scale (ESS), a standard questionnaire where people rate how likely they are to doze off in eight everyday situations; scores run from 0 to 24, with high...
View reported results on ClinicalTrials.gov ↗ · Linked publication on PubMed ↗
-
NCT05687903 · results posted 9 January 2025
According to the results reported on ClinicalTrials.gov, this trial enrolled 112 people across five groups to study a drug called TAK-861 in different doses for narcolepsy (a condition causing extreme daytime sleepiness and sudden muscle weakness). The five groups were: a placebo (dummy pill) group of 22 people, and four TAK-861 dose groups of 21–23 people each. The trial ran for 8 weeks and measured how long participants could stay awake during a formal test, how sleepy they felt on a standard questionnaire, how often they experienced cataplexy (sudden episodes of muscle weakness), and how ma...
Read the full trial page · View reported results on ClinicalTrials.gov ↗ · Linked publication on PubMed ↗
-
NCT05687916 · results posted 9 January 2025
According to the results reported on ClinicalTrials.gov, this trial (NCT05687916) enrolled 71 people in total, split across three groups: 24 received a placebo (a dummy treatment), 23 received a dose of TAK-861 called "2 mg BID" (meaning twice a day), and 24 received a varying dose of TAK-861 (starting at 2 mg and moving to 5 mg). The trial was measuring how well participants could stay awake, using a standard test called the Maintenance of Wakefulness Test (MWT), which records brain activity to track how long someone can resist falling asleep during 40-minute rest sessions. It also measured h...
Read the full trial page · View reported results on ClinicalTrials.gov ↗
-
NCT04096560 · results posted 29 October 2024
According to the results reported on ClinicalTrials.gov, this trial (NCT04096560) tested an investigational oral medicine called TAK-994 at different doses. It was organised into three parts (A, B, and C). In total, 97 people started the trial across all groups. Part A (22 people) focused on early monitoring of how the body responded to the medicine, comparing two doses of TAK-994 (120 mg and 180 mg) against a placebo (a dummy pill with no active ingredient). Parts B and C (90 people across several dose levels) looked at a measure called the Maintenance of Wakefulness Test (MWT) — a standard t...
View reported results on ClinicalTrials.gov ↗ · Linked publication on PubMed ↗
-
NCT04667338 · results posted 4 October 2024
According to the results reported on ClinicalTrials.gov, this trial (NCT04667338) enrolled 210 people in Spain who had been diagnosed with narcolepsy — 157 with Narcolepsy Type 1 and 53 with Narcolepsy Type 2. All 210 participants completed the study. The trial was not testing a new medicine; instead, it was an observational study designed to document what treatments people with narcolepsy were already receiving, and to gather information about their personal and health backgrounds. The reported data shows that the vast majority of participants in both groups had received some form of treatme...
-
NCT02611687 · results posted 19 September 2024
According to the results reported on ClinicalTrials.gov, this trial looked at a medicine called pitolisant in people with narcolepsy — a condition that causes extreme daytime sleepiness and, in some cases, sudden muscle weakness (called cataplexy). The trial had two phases: an 8-week phase where 72 people received pitolisant and 38 received a placebo (a dummy treatment with no active ingredient), followed by a longer open-label phase of more than 11 months where everyone received pitolisant. The trial measured changes in daytime sleepiness and narcolepsy symptoms using standard questionnaire-b...
View reported results on ClinicalTrials.gov ↗ · Linked publication on PubMed ↗
-
NCT04794491 · results posted 9 January 2024
According to the results reported on ClinicalTrials.gov, 62 people took part in this trial. All participants had already been taking a medication called Xyrem (sodium oxybate) and were switched to a similar medication called XYWAV (low-sodium oxybate). The trial was looking at how this switch affected the number of cataplexy attacks participants experienced each week — cataplexy being a sudden, brief loss of muscle control that can happen in people with narcolepsy. The trial also tracked things like nausea, daytime sleepiness, and how participants felt overall after the switch. Of the 62 who s...
View reported results on ClinicalTrials.gov ↗ · Linked publication on PubMed ↗
-
NCT04820842 · results posted 26 December 2023
According to the results reported on ClinicalTrials.gov, this trial (NCT04820842) tested different doses of an investigational drug called TAK-994 (at 30 mg, 90 mg, and 180 mg daily) across two phases. In the first phase — an 8-week period where all participants received the active drug — 8, 9, and 9 people started in the three dose groups respectively, though relatively few completed it (5, 1, and 2 people). A smaller number then moved into a second 4-week phase where some continued on TAK-994 and others were switched to a placebo (an inactive dummy treatment) without knowing which they were...
View reported results on ClinicalTrials.gov ↗ · Linked publication on PubMed ↗
-
NCT03881852 · results posted 24 August 2023
According to the results reported on ClinicalTrials.gov, this trial (NCT03881852) enrolled 21 people across two groups — 11 in Sequence 1 and 10 in Sequence 2. It was a crossover study, meaning participants took both the active treatment (AXS-12, also known as reboxetine) and a placebo (an inactive dummy treatment) at different points during the trial. The main thing being measured was the change in the average weekly number of cataplexy attacks (sudden episodes of muscle weakness) from the start of the study. The reported data shows that, on average, participants in the AXS-12 group had a re...
-
NCT02720744 · results posted 22 March 2022
According to the results reported on ClinicalTrials.gov, this trial looked at a treatment called FT218 compared to a placebo (a dummy treatment with no active ingredient) in people with narcolepsy — a condition that causes extreme daytime sleepiness and sudden episodes of muscle weakness called cataplexy. A total of 107 people were assigned to the FT218 group and 105 to the placebo group. Of those, 69 people in the FT218 group and 79 in the placebo group completed the trial. Three things were measured: how well people stayed awake during a standard test, how much their overall daytime sleepine...
Read the full trial page · View reported results on ClinicalTrials.gov ↗ · Linked publication on PubMed ↗
-
NCT02637076 · results posted 23 March 2021
According to the results reported on ClinicalTrials.gov, this trial enrolled 2 people with narcolepsy with cataplexy and 15 healthy volunteers (used as a comparison group). Of those, 1 person with narcolepsy and 10 healthy volunteers completed the study. The trial was measuring how a single 3-gram dose of Xyrem (sodium oxybate, a medication used for narcolepsy) affected dopamine activity in the brain, using a type of brain scan called a PET scan. The scans used special tracers — labelled chemicals that attach to specific targets in the brain — to estimate how much dopamine was present at diffe...
-
NCT02806908 · results posted 13 January 2021
According to the results reported on ClinicalTrials.gov, this trial (NCT02806908) enrolled 24 people in total — 11 in one group and 13 in the other — in a crossover design, meaning each participant took both JZP-110 (also known as solriamfetol) and a placebo at different times. Most participants finished the trial (10 and 12 respectively, with one dropout in each group). The trial was measuring how steadily people could keep a car in its lane during a simulated drive — a measure called "Standard Deviation of Lateral Position" (SDLP), which essentially tracks how much a vehicle weaves side to s...
View reported results on ClinicalTrials.gov ↗ · Linked publication on PubMed ↗
-
NCT03748979 · results posted 8 December 2020
According to the results reported on ClinicalTrials.gov, this trial (NCT03748979) tested a drug called TAK-925 at different doses given by infusion. It was split into several parts (Parts A, B, and C), and in total 57 people took part — all of whom completed the study with no drop-outs reported. The trial was primarily looking at how many participants experienced any unwanted medical events after receiving the drug or a dummy treatment (placebo), and secondarily at how the drug moved through the body (for example, how much of it appeared in the bloodstream) and how it affected people's ability...
-
NCT03030599 · results posted 12 November 2020
According to the results reported on ClinicalTrials.gov, this trial (NCT03030599) investigated a treatment called JZP-258 in people with narcolepsy, specifically looking at cataplexy (sudden episodes of muscle weakness) and daytime sleepiness. A total of 201 participants started the trial. The study had several stages: first, everyone received JZP-258 openly while the dose was adjusted, then those who were stable were randomly assigned — without knowing which they received — to either continue on JZP-258 (69 people) or switch to a placebo, meaning a dummy treatment with no active ingredient (6...
View reported results on ClinicalTrials.gov ↗ · Linked publication on PubMed ↗
-
NCT02348593 · results posted 23 July 2019
According to the results reported on ClinicalTrials.gov, this trial looked at a drug called JZP-110 in three different doses (75 mg, 150 mg, and 300 mg) compared to a placebo (a dummy pill with no active ingredient). A total of 236 people took part, split evenly into four groups of 59. The trial ran for 12 weeks and measured two main things: how long participants could stay awake during a controlled test called the Maintenance of Wakefulness Test (MWT), and how sleepy they rated themselves using a standard questionnaire called the Epworth Sleepiness Scale (ESS), where a higher score means more...
View reported results on ClinicalTrials.gov ↗ · Linked publication on PubMed ↗
-
NCT02348632 · results posted 25 June 2019
According to the results reported on ClinicalTrials.gov, this trial involved two stages. First, 643 people took part in an open-label period where everyone received the study drug, JZP-110. Of those, 458 completed this stage. Then, 282 participants moved into a second stage where they were randomly assigned to either continue with JZP-110 (140 people) or switch to a placebo — a dummy treatment with no active ingredient (142 people) — without knowing which they were receiving. The trial was measuring excessive daytime sleepiness, primarily using a questionnaire called the Epworth Sleepiness Sca...
View reported results on ClinicalTrials.gov ↗ · Linked publication on PubMed ↗
-
NCT02221869 · results posted 30 April 2019
According to the results reported on ClinicalTrials.gov, this trial (NCT02221869) involved children and adolescents with narcolepsy who experience cataplexy — sudden episodes of muscle weakness. A total of 106 participants were enrolled across three groups: 31 were randomly assigned to receive Xyrem (a medicine used for narcolepsy), 32 were randomly assigned to receive a placebo (a dummy treatment with no active ingredient), and 43 took part in an open-label phase where everyone received Xyrem. The main thing the trial was measuring was how the number of weekly cataplexy attacks changed when p...
View reported results on ClinicalTrials.gov ↗ · Linked publication on PubMed ↗
-
NCT02037438 · results posted 4 March 2019
According to the results reported on ClinicalTrials.gov, this trial enrolled 920 people in one group (called the "CONV Arm") and 916 people in another group (called the "PCCM Arm") — a total of 1,836 participants. The trial compared two different models of primary care over 12 months, measuring how patients rated their healthcare provider overall, how energetic and vital they felt, how well their provider communicated, and how useful they found their provider's use of technology such as computers and websites during their care. The reported data shows that when participants were asked to rate...
View reported results on ClinicalTrials.gov ↗ · Linked publication on PubMed ↗
-
NCT01681121 · results posted 11 September 2014
According to the results reported on ClinicalTrials.gov, this trial (NCT01681121) enrolled 93 people in total — 44 received a treatment called ADX-N05 and 49 received a placebo (a dummy treatment with no active ingredient). Of these, 36 in the ADX-N05 group and 38 in the placebo group completed the trial. The study was measuring two main things: how long participants could stay awake during a series of timed tests (called the Maintenance of Wakefulness Test, or MWT), and whether doctors rated participants' overall condition as improved compared to the start of the trial. The reported data sho...
View reported results on ClinicalTrials.gov ↗ · Linked publication on PubMed ↗
-
NCT01006122 · results posted 9 May 2014
According to the results reported on ClinicalTrials.gov, this trial enrolled 95 people in total (47 in one group, 48 in the other). It used a "crossover" design, meaning participants took the investigational drug — called PF-03654746 — for one period, then switched to a placebo (a dummy treatment with no active ingredient) for another period, or vice versa, with a washout break of at least seven days in between. The trial was looking at people with narcolepsy, a condition that causes severe daytime sleepiness and sudden muscle weakness (known as cataplexy). By the end of the study, 53 of the o...
-
NCT00132873 · results posted 25 November 2013
According to the results reported on ClinicalTrials.gov, this trial involved 59 people who were given a medication called Xyrem (sodium oxybate). Of those 59 participants, 50 completed the trial and 9 did not finish. The trial was measuring two main things over the course of one year: how many participants experienced side effects or unwanted reactions (called "treatment-emergent adverse events"), and what participants' breathing rates were at the end of the year. The reported data shows that 54 out of 59 participants experienced at least one treatment-emergent adverse event — that is, an unw...
-
NCT01183312 · results posted 27 March 2013
According to the results reported on ClinicalTrials.gov, this trial involved 10 people in total, split into two groups of five. It used a "crossover" design, meaning everyone tried both treatments — a sublingual (dissolved under the tongue) form of flumazenil and a placebo (inactive treatment) — with at least a week's break in between. The trial was measuring alertness and reaction speed using a computerised task called the Psychomotor Vigilance Task (PVT), which asks people to press a button as quickly as possible when a visual signal appears on a screen. The reported data shows that for the...
-
NCT00066170 · results posted 30 November 2011
According to the results reported on ClinicalTrials.gov, this trial enrolled 231 people in total across four groups. Participants were people with narcolepsy (a condition causing excessive daytime sleepiness) who were randomly assigned to receive either: a placebo (dummy treatment) for both medications; Xyrem (sodium oxybate) with a placebo for the other medication; modafinil at their usual established dose with a placebo for the other medication; or both Xyrem and modafinil together. The trial was measuring how well participants could stay awake during the daytime, tested over 8 weeks. The r...
View reported results on ClinicalTrials.gov ↗ · Linked publication on PubMed ↗
-
NCT00228553 · results posted 31 March 2010
According to the results reported on ClinicalTrials.gov, this trial enrolled 743 people who were taking armodafinil (at doses of 100 to 250 mg per day) for one of three sleep-related conditions: narcolepsy (a condition causing sudden, uncontrollable sleepiness), obstructive sleep apnoea/hypopnoea syndrome (where breathing repeatedly stops during sleep), or shift work sleep disorder (disrupted sleep caused by working non-standard hours). The trial ran for up to two years and had a single group — there was no comparison or placebo group reported. Of the 743 people who started, 313 completed the...
Read the full trial page · View reported results on ClinicalTrials.gov ↗
-
NCT00078312 · results posted 22 February 2010
According to the results reported on ClinicalTrials.gov, this trial involved 328 people who all received armodafinil (at doses ranging from 100 to 250 mg per day). There was only one group in this study — meaning everyone received the same treatment, with no comparison or placebo group. The trial was measuring the safety and tolerability of armodafinil by tracking how many participants experienced adverse events (that is, unwanted or unexpected medical occurrences during the study). Of the 328 people who started, 151 completed the study and 177 did not complete it. The reported data shows tha...
These are the results as reported to the registry, not medical advice. Verify independently with the trial site and discuss what they mean for you with your doctor.
What is coming
AI generated pipeline summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
According to NIH funding data, public research investment in narcolepsy sits at a moderate level, which suggests the condition has attracted meaningful scientific attention from government sources. However, the direction of that funding has been falling year on year, meaning researchers working in this space may find it harder to secure support going forward. For patients, this trend is worth watc...
Not medical advice. Voxsanity republishes public government health data in plain English. These figures describe research and registry activity, not the suitability of any treatment for any person. Trial status can change; always verify current status directly with the trial site and confirm Australian availability with your doctor.